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Background: The VELETI trial (ClinicalTrials.gov number: NCT00289835) showed that sealing moderate non-significant saphenous vein graft (SVG) 
lesions with paclitaxel-eluting stents (PES) was effective and safe for preventing SVG atherosclerosis progression at 1-year follow-up. The objective of the 
present study was to determine the incidence of major adverse cardiac events (MACE) related to the target SVG at 3-year follow-up in the VELETI trial.
Methods: Patients with at least one moderate SVG lesion (diameter stenosis: 39 ± 7%) were randomized to either stenting the SVG lesion 
with a PES (n=30, PES group) or to medical treatment (n=27, MT group). MACE (cardiac death, myocardial infarction [MI], clinically driven 
revascularization) were determined peri-procedurally and yearly after the intervention, and further classified as related or not to the target SVG.
Results: Mean age of the study population was 69 ± 8 years, mean time from CABG was 12 ± 6 years, and mean LDL cholesterol level was 73 
± 31 mg/dL. A total of 57 SVGs with 70 moderate SVG lesions were evaluated. Patients in the PES group received 1.3 stents per patient, SVG-
PCI was susccessful in all cases and 1 patient (3%) complicated with a post-procedural non-ST elevation MI. No peri-procedural complications 
occurred in the MT group (p=1.0 vs. PES group). During a median follow-up of 35 months (IQR: 26 to 37 months), MACE rate related to the target 
SVG was 26% in the MT group (cardiac death: 0%, MI: 7%, revascularization: 26%) compared to 3% in the PES group (cardiac death: 0%, MI: 3%, 
revascularization: 3%); p=0.02. MACE in the MT group occurred at a mean of 15 ± 12 months and were related to SVG disease progression leading 
to a severe flow-limiting SVG lesion or SVG occlusion (mean % diameter stenosis: 73 ± 18%). MACE in the PES group were due to a late restenosis 
that occurred in 1 patient at 26-month follow-up. There were no cases of stent thrombosis.
Conclusions: Moderate non-significant lesions in old SVGs are at very high-risk of progression and clinical events within 2 years. Plaque sealing 
of such lesions with PES was associated with a reduction of MACE at 3-year follow-up. This pilot study supports further investigation into the role of 
plaque sealing in SVGs.
